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Text A neurotrophic hypothesis has been recently proposed to explain the molecular effects of
antidepressant drugs. Chronic antidepressant treatment with selective serotonin re-uptake inhibitors
(SSRIs) induces an increase in the expression of some neurotrophic factors such as brain derived
neurotrophic factor (BDNF). An increase of the proliferation marker beta-catenin has also been
associated to antidepressant treatment. Both BDNF and beta-catenin have been correlated to a
higher cell proliferation in the dentate gyrus (DG) of the hippocampus. It has been proposed that the
coadministration of SSRIs and 5-HT2A antagonists could enhance antidepressant responses leading
to an early-onset of action.
In this work we have studied the effects of a subchronic treatment (7 days) with fluoxetine (5
mg/kg/day; i.p.) and fluoxetine+ketanserine (association group, 0.1 mg/kg/day; i.p.) on mRNA
expression of BDNF and TrkB (in situ hybridization), cell proliferation in the DG of the hippocampus
(BrdU incorporation), beta-catenin levels in hippocampus (Western blot) and 5-HT2A receptor
functionality ([35S]GTPgammaS labeling). Forced swimming test (FST) was also carried out to
confirm the antidepressant response.
In contrast with the results of the fluoxetine group, BDNF expression increased significantly in the
association group in the CA3 (130±16%; p<0.05) and DG (146±22%; p<0.05) of the hippocampus,
without modification in TrkB expression. There were no significant changes in 5-HT2A receptor
functionality. As well, BrdU labeling was not significantly modified, although there was a tendency to
the increase in the association group. A clear increase in beta-catenin expression was observed in
the association group in total homogenate (120±7%; p<0.05) and membrane (134±9%; p<0.001)
fractions of the hippocampus, in contrast to the lack of changes in the fluoxetine-treated animals. The
coadministration of fluoxetine+ketanserine also produced a reduction in the immobility time in the FST
when compared to the vehicle group (p<0.05).
These results suggest that 5-HT2A antagonism could contribute to an increase in neural plasticity
prior to SSRI-induced proliferative changes in hippocampus, as a mechanism for a short-acting
response.
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